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Summary
Clear cell sarcoma (CCS) harbors a pathognomonic chromosomal translocation fusing the Ewing’s sarcoma gene (EWS) to
the CREB family transcription factor ATF1 and exhibits melanocytic features. We show that EWS-ATF1 occupies the MITF
promoter, mimicking melanocyte-stimulating hormone (MSH) signaling to induce expression of MITF, the melanocytic mas-
ter transcription factor and an amplified oncogene in melanoma. Knockdown/rescue studies revealed that MITF mediates
the requirement of EWS-ATF1 for CCS survival in vitro and in vivo as well as for melanocytic differentiation. Moreover,
MITF and TFE3 reciprocally rescue one another in lines derived from CCS or pediatric renal carcinoma. Seemingly unrelated
tumors thus employ distinct strategies to oncogenically dysregulate the MiT family, collectively broadening the definition of
MiT-associated human cancers.Introduction
MITF, TFE3, TFEB, and TFEC comprise a family of transcription
factors that share a highly homologous basic-helix-loop-helix-
leucine zipper (bHLHzip) DNA binding and dimerization domain
(reviewed in Steingrimsson et al., 2004). These proteins homo-
or heterodimerize in all combinations and bind identical DNA el-
ements (Beckmann and Kadesch, 1991; Fisher et al., 1991;
Hemesath et al., 1994), suggesting that they may activate com-
mon downstream targets. Indeed, elegant knockout studies
have demonstrated the functional redundancy of MITF and
TFE3 in modulating murine osteoclast development (Steing-
rimsson et al., 2002).
TheMiT family is critical for the normal development of several
cell lineages (reviewed in Steingrimsson et al., 2004). In melano-
cytes, MITF is a target of the melanocyte-stimulating hormone
(MSH) pathway. MSH stimulation increases intracellular cAMP,CANCER CELL 9, 473–484, JUNE 2006 ª2006 ELSEVIER INC. DOI 10.10resulting in CREB/ATF1-mediated activation of the MITF pro-
moter (Bertolotto et al., 1998; Price et al., 1998). Consistent
with evidence that MITF is a master regulator of differentiation
in the melanocyte lineage, MITF may mediate the well-docu-
mented role ofMSH in themodulation of pigmentationby regulat-
ingmany of the genes involved inmelanin biosynthesis, including
tyrosinase, tyrosinase-related protein 1, dopachrome tautomer-
ase, and AIM-1 (Bentley et al., 1994; Du and Fisher, 2002; Hem-
esath et al., 1994; Yasumoto et al., 1994).
However, homozygous MITF deficiency in the mouse results
in loss of the melanocyte lineage, rather than albinism (pigment
deficiency in viable melanocytes), suggesting that the functions
of MITF extend beyond regulation of pigmentation. In humans,
heterozygous mutation of MITF produces Waardenburg syn-
drome IIa, which is characterized by white spotting due to me-
lanocyte deficiencies (Hughes et al., 1994; Moore, 1995; Price
and Fisher, 2001; Tachibana, 1997; Tassabehji et al., 1994).S I G N I F I C A N C E
MITF, TFE3, TFEB, and TFEC comprise a conserved and discrete bHLHzip transcription factor family (MiT).MITF amplification inmelanoma
and TFEB or TFE3 translocation in certain pediatric solid tumors suggest a role for the MiT family in oncogenesis. This study extends the
definition of MiTmalignancies by demonstrating amechanism for oncogenicMITF dysregulationwithout amplification or translocation:
direct targeting by the EWS-ATF1 fusion protein. Families composed of seemingly unrelated tumors employing distinct strategies of on-
cogene activation may occur more broadly than previously recognized. For the MiT family, this mechanism suggests that common
transcriptional targets are important for oncogenic growth/survival.16/j.ccr.2006.04.021 473
A R T I C L EConsistent with its vital role, MITF has been suggested to regu-
late genes important for cell proliferation and survival including
BCL2, CDK2, p16/Ink4a, c-MET, and p21CIP (Carreira et al.,
2005; Du et al., 2004; Loercher et al., 2005; McGill et al., 2002,
2006). TFEB knockout produces early embryonic lethality with
placental defects (Steingrimsson et al., 1998).
Recently, MiT family gain of function has been directly impli-
cated in tumorigenesis. Approximately 20% of melanomas har-
bor amplification of the MITF gene, in some cases exceeding
100 copies, and disruption of MITF activity is lethal to melanoma
cells (Garraway et al., 2005). Furthermore, MITF overexpression,
in combination with other oncogenic lesions in human melano-
cytes, enhances growth factor-independent transformation and
confers anchorage-independent growth.TFEBandTFE3 translo-
cations have been identified in pediatric renal carcinoma and al-
veolar soft part sarcoma (Argani et al., 2001, 2003; Clark et al.,
1997; Davis et al., 2003; Heimann et al., 2001; Kuiper et al.,
2003b; Sidhar et al., 1996; Weterman et al., 1996). The TFEB
translocation is particularly informative, since its 50 fusion partner
provides a strong promoter but contributes no protein-encoding
sequence, suggesting an oncogenic role arising solely from dys-
regulated expression. Thus, two mechanisms—amplification or
translocation—dysregulate MiT oncogenes in human cancers.
Clear cell sarcoma (CCS) is a soft tissuemalignancy of tendons
andaponeuroses in young adults (Enzinger, 1965) that is typically
unresponsive to chemotherapy or radiotherapy (Deenik et al.,
1999; Ferrari et al., 2002; Finley et al., 2001). Although a sarcoma,
CCS contains premelanosomes, expresses immunohistochemi-
cal markers of melanocytic differentiation (e.g., HMB45), and in
some cases produces melanin (Antonescu et al., 2002; Chung
and Enzinger, 1983; Granter et al., 2001; Swanson and Wick,
1989). CCS is definedmolecularly by a unique cytogenetic trans-
location joining the Ewing’s sarcoma-associated gene (EWS) to
activating transcription factor 1 (ATF1) (Balaban et al., 1984; Lan-
gezaal et al., 2001; Zucman et al., 1993). ATF1 is amember of the
CREB transcription factor family, whose activity is regulated by
protein kinase A or RSK-mediated serine phosphorylation of
the kinase-inducible domain (KID) (reviewed in Mayr and Mont-
miny, 2001; Shaywitz andGreenberg, 1999). InCCS, anEWS-de-
rived domain with strong activation activity replaces the KID of
ATF1, resulting in a chimeric transcription factor that retains
normal cAMP-responsive element (CRE) DNA binding but trans-
activates in a cAMP-independent fashion (Brown et al., 1995;
Fujimura et al., 1996; Lessnick et al., 1995).
In melanocytes, MSH-induced MITF expression requires a
CRE located within the melanocyte-specific promoter (M-MITF)
that directs expression of a melanocyte-specific first exon (Fig-
ure 1A) (Bertolotto et al., 1998; Price et al., 1998). Additional
MITF isoforms derive from alternative upstream promoter/first
exon units, some (i.e., A-MITF) located as far as w200 kb up-
stream of shared exon 2 (Fuse et al., 1996; Hershey and Fisher,
2005;Shibahara et al., 1999).CREB/ATF1-mediatedM-MITFac-
tivation displays lineage restriction characterized by an inability
to respond to cAMPsignaling in nonmelanocytic cells (Bertolotto
et al., 1998; Price et al., 1998). Tissue-specific M-MITF expres-
sion involves cooperativity between CREB/ATF1 and the neural
crest-restricted transcription factor SOX10 (Huber et al., 2003).
As with MITF, SOX10 mutation results in Waardenburg syn-
drome (Price and Fisher, 2001).
Several previous studies have identified the expression of
MITF protein or mRNA in CCS (Granter et al., 2001; Koch474et al., 2001; Antonescu et al., 2002; Li et al., 2003; Schaefer
et al., 2004; Segal et al., 2003). These have included immunohis-
tochemical staining as well as RNA and Western blotting analy-
ses, the latter two demonstrating presence of the melanocytic
MITF isoform (Antonescu et al., 2002; Li et al., 2003). However,
the mechanism of M-MITF regulation in CCS as well as its func-
tion are unknown.
Results
MITF expression in clear cell sarcoma
Immunohistochemical analysis revealed nuclearMITF in theCCS
primary tumor from which the cell line CCS292 was derived
(Figure 1B), in agreement with previous reports for melanoma
and CCS (Antonescu et al., 2002; Granter et al., 2001; King
et al., 1999; Koch et al., 2001). RNA and protein were examined
from three human CCS lines, and all were found to express the
melanocyte-specific MITF isoform protein and mRNA (Figures
1C and 1D), in agreement with RNA and protein expression re-
sults from primary tumor samples and other cell lines (Antonescu
et al., 2002; Li et al., 2003; Schaefer et al., 2004; Segal et al.,
2003). CCS cells also express variable quantities of a larger
isoform that comigrates with A-MITF, a more ubiquitously
expressed isoform seen in a variety of cell types including mela-
noma and the RAW264.7 leukemia cell line (Figure 1C) (Weil-
baecheret al., 2001). In contrast, neitherMITF isoform isdetected
in the Ewing’s sarcoma cell line, which expresses the EWS-FLI1
oncoprotein. The identification of the melanocyte-specific
M-MITF isoform in several CCS cell lines prompted examination
of the mechanism underlying its expression in this tumor.
EWS-ATF1 regulates the MITF promoter
The melanocyte-specific MITF promoter contains a CRE site
and recognition elements for SOX10, PAX3, and TCF/LEF
(Figure 1A) (reviewed in Steingrimsson et al., 2004). To examine
the possibility that EWS-ATF1 may bind the endogenous M-iso-
form promoter, chromatin from three CCS cell lines (expressing
EWS-ATF1; Figure S1A in the Supplemental Data available with
this article online and data not shown) or a Ewing’s sarcoma cell
line (control) was immunoprecipitated using EWS-selective anti-
body. As shown in Figure 2A, EWS-ATF1 occupied theM-MITF
promoter in all three CCS lines, whereas chromatin fromEwing’s
sarcoma failed to show similar occupancy for EWS-FLI1. Fur-
thermore, MITF promoter occupancy was demonstrated by
ChIP using N-terminus-specific EWS antibodies but not C-ter-
minal specific antibodies, consistent with the EWS domain pre-
served in the EWS-ATF1 fusion (Figure 2B).
If EWS-ATF1 regulatesMITF through the melanocyte-specific
MITF promoter, the MITF promoter should be constitutively
active in a manner dependent upon its CRE sequence but
independent of cAMP levels. To test this, the M-MITF promoter
directing luciferase expression (Price et al., 1998) was used in re-
porter assays. This reporter was active in all three CCS lines and
dependent upon its CRE (Figure 2C). In contrast, the same
M-MITF promoter was relatively inactive in Ewing’s sarcoma
cells, and its basal activity was not affected by CRE mutation.
We then examinedM-MITFpromoter responsiveness to cAMP
induction in bothCCSandmelanomacells (aspositive control). In
melanoma cells,MITF promoter activity was significantly stimu-
lated by the cAMP agonist forskolin (Figure 2D), mimicking
MSH signaling, as previously reported (Price et al., 1998).CANCER CELL JUNE 2006
A R T I C L EFigure 1. M-MITF expression in clear cell sarcoma
A: The MITF locus showing the melanocyte-spe-
cific promoter/exon-1 (M-MITF) with its consensus
CRE. Location of primers used for MITF chromatin
immunoprecipitation (blue) and RT-PCR (purple)
are shown.
B: Hematoxylin and eosin and MITF immunostain
of primary tumor from which the CCS292 line was
derived shows a sheet of tumor cells with strong
nuclear reactivity for MITF (bar = 0.1 mm).
C: Extracts of CCS (DTC-1, SU-CCS-1, and
CCS292), melanoma (501mel), myelomonocytic
leukemia (RAW264.7), or Ewing’s sarcoma
(EWS502) lines were subjected to Western blot
analysis with monoclonal anti-MITF antibody
(Weilbaecher et al., 1998).
D: RNA from indicated cells was subjected to
RT-PCR with M-form MITF-specific and GAPDH
(control) primers.In CCS cells the MITF promoter was constitutively active (Fig-
ure 2D) and was not further stimulated by forskolin treatment,
despite the requirement of the CRE element (Figure 2D and
Figure S1A). Nonetheless, forskolin induced CREB phosphoryla-
tion in CCS cells (Figures S1A and S1C). Moreover, inhibition of
PKA by treatment with H89 had little effect onMITF promoter ac-
tivity despite inhibiting CREB activation (Figures S1C and S1D).
cAMP induction did not significantly affect EWS or EWS-ATF1
levels (Figure S1A). These results demonstrate that the M-MITF
promoter is active inCCScells in aCRE-dependentbut cAMP-in-
dependentmanner, a combination of behaviors perfectly match-
ing the predicted activity of EWS-ATF1 on theMITF promoter.
Regulation of endogenous MITF by EWS-ATF1
Given the CRE dependence of theM-MITF promoter for consti-
tutive activation in CCS cells (Figures 2C and 2D), we askedCANCER CELL JUNE 2006whether endogenous MITF expression was similarly regulated
by EWS-ATF1. Inhibition of EWS-ATF1 was achieved through
use of dominant-negative CREB (DNCREB). Mutation of CREB
at serine 133, the phosphorylation site that mediates coactivator
recruitment and transactivation (Gonzalez andMontminy, 1989),
results in strong dominant-negative activity because it retains
the dimerization interface but is transcriptionally inactive (Lamph
et al., 1990). Expression of DNCREB in CCS cells resulted in po-
tent and selective inhibition of M-MITF expression (Figure 2E).
Notably, the ubiquitous A form not only continued to be ex-
pressed but was somewhat increased in the presence of
DNCREB-encoding adenovirus. These results demonstrate the
selective dependence of the M-MITF promoter on CREB-like
activity and, together with reporter-based assays, that EWS-
ATF1 is a necessary transactivator of the M-MITF promoter
in CCS.475
A R T I C L EFigure 2. Transcriptional regulation of the MITF promoter
A:Chromatin isolated from CCS (DTC-1, SU-CCS-1, or CCS292) or Ewing’s sarcoma (EWS502) cells was immunoprecipitated with anti-EWS antibody, anti-CDK2
antibody (control), or no antibody and then amplified with M-MITF promoter-specific primers. Input control indicates amplified total DNA.
B:CCS (DTC-1) chromatin was immunoprecipitated with antibody directed to either the amino (N) or the carboxyl (C) domain of EWS and then quantitatively
amplified with M-MITF-specific primers. The ratio of immunoprecipitated versus input control and nonquantitative electrophoresis results are shown.
C: The activity of the M-MITF promoter (Mitf), the identical sequence with mutated CRE [Mitf(Dcre)] or vector control (pGL2) were assayed after transfection by
luciferase quantification and normalized to an internal control (pRL).
D: Melanoma (B16) or CCS (CCS292) cell lines were transfected with the M-MITF promoter (Mitf), mutant CRE [Mitf(Dcre)], or vector control. Cells were treated
with forskolin for 24 hr prior to luciferase assay.
E: CCS cells were infected with an MOI of 50, 100, or 200 of either control adenovirus or adenovirus encoding dominant-negative CREB (DNCREB). Tubulin
serves as a control for cell viability. UI, uninfected cells.
Error bars represent 6 standard deviation (SD).MITF activation requires SOX10 expression
In melanocytes, tissue-specific CRE response of the MITF pro-
moter requires cooperativity with the transcription factor
SOX10 (Huber et al., 2003). We therefore asked whether SOX10
also participates in MITF expression in CCS cells. Three CCS
cell lines and a melanoma cell line—but not Ewing’s sarcoma or
neuroblastoma cell lines—were found to express SOX10
(Figure 3A). In a dose-dependent fashion, a naturally occurring
dominant-negative mutant, SOX10dom (Pingault et al., 1998;
Southard-Smith et al., 1998), specifically abrogated MITF476promoter activity (Figure 3B). In 293 cells (lacking endogenous
SOX10), ectopic EWS-ATF1 failed to activate the M-MITF
promoter (Figure 3C), whereas ectopic SOX10 enabled EWS-
ATF1-mediated activation. SOX10 alone also measurably
activated theMITF promoter, likely via cooperativity with endog-
enous activated CREB, as previously described (Huber et al.,
2003). These data demonstrate dependence on SOX10 for
CRE-mediated transactivation of the M-MITF promoter in CCS
and also suggest that the normal cellular counterpart of CCS
maybe a SOX10-expressing lineage (i.e., neural crest derivative).CANCER CELL JUNE 2006
A R T I C L EFigure 3. EWS-ATF1 activity on the M-MITF pro-
moter is SOX10 dependent
A: Extracts of CCS, Ewing’s sarcoma, melanoma,
or neuroblastoma cells were immunoblotted
with anti-SOX10 antibody. An uncharacterized
cross-reactive band is shown in CCS292 (*).
B: CCS cells (DTC-1) were transfected with
increasing amounts of vector (pCDNA3) direct-
ing expression of an inactive form of SOX10
(SOX10dom) together with either vector (pGL2)
or the M-MITF promoter (Mitf). Total DNA content
was identical for all conditions. Luciferase activity
is shown relative to an internal control (pRL).
C: Vector (pcDNA3) or wild-type SOX10 and
either vector (pcDNA3) or EWS-ATF1 type I (EWS/
ATF) were cotransfected into HEK293 cells
together with vector (pGL2), M-MITF promoter
(Mitf), CRE mutant (MitfDCRE), or SOX10 binding
site mutant (MitfDSOX).
Error bars represent6 SD.MITF confers melanocytic differentiation
in clear cell sarcoma
To examine the role of MITF in the melanocytic differentiation of
CCS, we suppressed endogenous EWS-ATF1 activity with
DNCREB. In addition, MITF activity was modulated with either
full-length MITF or a dominant-negative mutant lacking the 50
transactivation domain and incorporating a basic region muta-
tion that prevents DNA binding (Widlund et al., 2002). This
MITF mutant retains the ability to dimerize through an intact
HLHzip domain and sequesters wild-type partners in non-DNA
binding complexes but has no effect on the MYC family of E
box binding transcription factors. Modulation of MITF activity
did not affect EWS-ATF1 levels (Figure S1E). To test whether
EWS-ATF1 or MITF inhibition affects endogenous MITF target
gene expression, quantitative reverse transcriptase-polymerase
chain reaction (RT-PCR) assays were performed on RNA de-
rived from adenovirus-infected CCS cells. Given the signifi-
cance of HMB45 immunostaining for the pathological identifica-
tion of CCS and the identification of PMEL17 (the gene encoding
the HMB45 antigen) as an MITF target (Du et al., 2003), we ex-
amined PMEL17 expression. As shown in Figure 4A, PMEL17
expression was modestly increased by MITF overexpression,
whereas DNMITF significantly reduced PMEL17 mRNA levels.
Inhibition of EWS-ATF1 similarly decreased PMEL17 expres-
sion, whereas coexpression of MITF overcame this effect in
a dose-dependent fashion (Figure 4B). DNMITF also inhibited
expression of the MITF target gene and melanocytic marker
MLANA (Figure S1E). These experiments suggest that pigment
gene expression in CCS is downstream of EWS-ATF1 via direct
regulation by MITF.CANCER CELL JUNE 2006We then examined the roles of MITF and EWS-ATF1 on the
pigmented phenotype. To quantitatively assay pigmentation,
we spectrophotometrically monitored the conversion of unco-
lored 3,4-dihydroxy-L-phenylalanine (L-DOPA) substrate to
darkly colored dopaquinone, a direct measure of tyrosinase ac-
tivity, the rate-limiting enzyme in melanin biosynthesis, in CCS
cell extracts (Cooksey et al., 1997; Oetting et al., 1998). As
shown in Figure 4C, disruption of endogenous MITF decreased
tyrosinase activity, whereas overexpression of wild-type MITF
induced tyrosinase activity. Similarly, disruption of EWS-ATF1
resulted in significantly diminished pigmentation (Figure 4D). Im-
portantly, coexpression of MITF in EWS-ATF1-inhibited cells
significantly rescued pigmentation (Figure 4E). Although domi-
nant-negative CREB lacks specificity for EWS-ATF1, that MITF
can rescue pigmentation in the context of CREB family inhibition
demonstrates the importance of MITF for pigmentation and
suggests that EWS-ATF1 acts through MITF to mediate the
melanocytic differentiation characteristic of CCS.
MITF activity is necessary for tumor cell proliferation
We hypothesized that the targeting of MITF by EWS-ATF1 may
be critical for proliferation or survival of CCS. To test this, we in-
hibited EWS-ATF1 or MITF activity in CCS cells using retrovirally
transduced dominant-negative forms of these proteins as well
as shRNA. Infected cells were cultured in soft agar under condi-
tions selective for viral transduction. Whereas CCS colonies
developed from cells infected with the parental virus, colony for-
mation was virtually abrogated in CCS cells expressing either
DNCREB or DNMITF (Figure 5A). The integrity of the viruses
was confirmed by performing identical growth assays on477
A R T I C L EFigure 4. MITF regulates CCS pigmentation
A: PMEL17 expression from CCS (CCS292) cells in-
fected with adenovirus expressing a control
polypeptide (Control), MITF, or DNMITF was
quantitated by RT-PCR and normalized to
GAPDH RNA levels.
B: CCS cells were infected with adenovirus en-
coding DNCREB and increasing MOI of adenovi-
rus encoding MITF.
C: Extracts of uninfected (UI) or CCS cells in-
fected with an MOI of 50 to 200 of adenovirus ex-
pressing either MITF or DNMITF were assayed for
enzymatic conversion of DOPA to dopaquinone
at 48 and 72 hr, respectively. Slope of the OD ver-
sus time curve is plotted.
D:No extract (2), extracts of uninfected (UI) cells,
or extracts of CCS292 cells infected with an MOI
of 50 to 200 of DNCREB-expressing adenovirus
were assayed for DOPA conversion at 72 hr.
E: Extracts of CCS292 cells infected with the high-
est MOI of DNCREB from D were coinfected with
MITF or control vector and assayed for DOPA
conversion at 72 hr. Representative triplicate mi-
crotiter well assays are shown to the left. Quanti-
tation of DOPA conversion is shown to the right.
Error bars represent 6 SD.similarly infected Ewing’s sarcoma cells as controls. This exper-
iment demonstrates that both EWS-ATF1 and MITF activity are
necessary for CCS survival and/or proliferation.
To specifically examine the role of MITF in tumor cell survival,
CCS cells were transfected with plasmid expressing the
MITF-directed shRNA or a control shRNA (Figure 5B). MITF
knockdown significantly decreased cell viability (Figure 5C). To
examine MiT family functional redundancy in this setting, we as-
sessed the ability of alternate MiT family members to rescue the
lethal effects of MITF knockdown by cotransfecting plasmids
encoding TFEB or TFE3 together with MITF shRNA. TFEB
expression completely rescued viability in a dose-dependent
fashion (Figure 5C), as did TFE3 cotransfection (data not
shown). Taken together with the effect of dominant-negative478MITF on growth in soft agar, these data demonstrate that
MITF is necessary for CCS viability in a manner that can be
functionally replaced by other MiT members.
As a complementary test of the functional overlap of MiT
oncogenes, we utilized TFE3-directed shRNA (Figure 5D) to de-
termine the requirement for TFE3 for the growth/survival of
a TFE3-translocated renal carcinoma cell line. Transfection of
TFE3-directed shRNA into a renal cell carcinoma cell line that
harbors the NonO-TFE3 translocation but fails to express wild-
type TFE3 (UOK109; Clark et al., 1997) prevented virtually all
colony growth (Figure 5E). However, cotransfection of ectopic
MITF efficiently rescued colony formation, demonstrating that,
in the context of translocation-associated renal cell carcinoma,
MITF can replace translocated TFE3.CANCER CELL JUNE 2006
A R T I C L EFigure 5. MiT family members demonstrate functionally redundant oncogenic activity in CCS and renal carcinoma
A: CCS292 or Ewing’s sarcoma (EWS502) cells were infected with either empty retrovirus (Vec) or retrovirus expressing either DNCREB or DNMITF. Cells were
briefly cultured, then plated in soft agar containing G418. Visible colonies were counted.
B: CCS (SU-CCS-1) cells were transfected with 1–3 mg plasmid (pSuper; Vec) expressing either MITF-directed (shMITF) or luciferase-directed (control) shRNA.
Extracts of unselected cells were analyzed for MITF or tubulin (control) expression.
C:CCS cells (SU-CCS-1) were transfected with 1–3 mg pSuper (Vec) or pSuper expressing shMITF and either pcDNA3 (Vec) or pCDNA3 encoding TFEB, as well as
0.5 mg pcDNA3 encoding GFP. Two days after transfection, trypan-negative cells were counted, and transfection efficiency was assayed by FACS. The per-
cent GFP-positive and trypan-negative is shown.
D: Lysates of GFP-cotransfected, sorted UOK109 cells transfected with plasmid expressing TFE3 shRNA or control shRNA were analyzed with anti-TFE3 or anti-
tubulin (control) antibody.
E: TFE3-translocated renal carcinoma cells (UOK109) were transfected with TFE3-directed or luciferase-directed (control) shRNA together with either vector
(pcDNA) or plasmid encoding MITF as well as pBABEpuro (4 mg total plasmid/well). Puromycin-resistant colonies were stained with crystal violet and counted.
Photographs of representative wells are shown.
Error bars represent 6 SD.MITF mediates EWS-ATF1-induced tumor growth
Although it is likely that the EWS-ATF1 translocation product ab-
errantly regulates numerousCREB/ATF-regulated genes,wehy-
pothesized that MITF may be both necessary and sufficient to
explain the effect of EWS-ATF1 on CCS cell growth and survival.
To test this hypothesis, we designed shRNA directed toward the
EWSdomainofEWS-ATF1 (Figure6A).Retroviral transductionof
CCS with EWS-directed shRNA resulted in a significant de-
crease in the number of colonies in soft agar (Figure 6B) with in-
complete suppression of colony formation likely reflecting partial
EWS-ATF1 knockdown. Importantly, exogenous MITF expres-
sion in the presence of the EWS-targeted shRNA significantly
rescued colony formation. Control cells (HeLa) lacking an EWS
translocation, when transduced with EWS-directed or control
shRNA, failed to demonstrate a similar decrease in cell viability.
To extend these analyses to CCS tumor growth in vivo, we
generated a xenograft model. Luciferase-expressing CCS tu-
mor cells implanted into mice reproducibly demonstratedCANCER CELL JUNE 2006measurable and sustained logarithmic tumor growth (Figure 6C).
Equal numbers of CCS cells were transduced with retrovirus
expressing EWS-directed shRNA and retrovirus encoding
MITF (or controls). After 48 hr of ex vivo puromycin selection,
the cell population was subcutaneously implanted, and tumor
growth was monitored quantitatively. EWS shRNA potently
inhibited in vivo tumor growth, whereas coexpression of MITF
rescued the growth-suppressive effect of EWS-ATF1 knock-
down (Figure 6D). Taken together with the direct targeting of
MITF by EWS-ATF1, these data strongly suggest that MITF is
both a necessary and sufficient target gene mediating the onco-
genic activity of EWS-ATF1 on CCS growth.
Discussion
Our studies demonstrate that the melanocyte-specific MITF
promoter is occupied and constitutively activated by EWS-
ATF1 in CCS. M-MITF promoter activity is CRE dependent in479
A R T I C L EFigure 6. MITF rescues EWS knockdown-mediated loss of cell viability in soft agar and in vivo
A: CCS292 cells transfected with luciferase-directed (control) or EWS-directed shRNA together with GFP were sorted and analyzed for knockdown efficiency
with anti-EWS or anti-tubulin (control) antibody.
B:CCS292 or HeLa (control) cells were infected with retrovirus expressing luciferase-directed (control) or EWS-directed (shEWS) shRNA in the presence of either
control or MITF-expressing retrovirus (vector). Cells were cultured under selective conditions in soft agar, and colonies were counted.
C: Luciferase-expressing CCS cells (CCS292) were injected subcutaneously into nude mice. Mice were imaged at the indicated days, and photonic emission
was quantitated. False-color heat map representations of photonic emission overlaying photographs of mice are shown.
D: Luciferase-expressing CCS292 cells were transduced with retrovirus expressing EWS-directed shRNA and puromycin N-acetyl transferase together with
either control retrovirus or retrovirus encoding MITF. After a 48 hr period of antibiotic selection, cells were injected subcutaneously into nude mice and
then imaged on the indicated days.
Error bars represent 6 SD.the absence of a cAMP requirement, an unusual scenario ex-
plained by the cAMP independence but CRE dependence of
the EWS-ATF1 fusion oncoprotein (Brown et al., 1995). These
findings contrast those of Li et al., who failed to identify measur-
able M-MITF promoter activity using reporter plasmid-based
assays in transfected CCS cells, despite demonstrating that
the same cells express M-MITF protein (Li et al., 2003). This dis-
crepancy likely results from significant differences in reporter
construction, transfection techniques, and assay conditions.
Our data are complemented by the demonstration that endoge-
nous MITF expression levels are coordinately regulated in re-
sponse to modulation of EWS-ATF1 activity. Furthermore, we
show that MITF is critical for both melanocytic differentiation
and growth/survival of CCS.
The relationship between CCS and melanoma has been un-
certain, since the initial characterization of CCS (Chung and
Enzinger, 1983; Enzinger, 1965). Given that many of the genes
associated with melanocytic differentiation are targets of
MITF, EWS-ATF1-mediated activation of MITF likely explains480the melanocyte differentiation profile exhibited by these tumors.
Prior reports are consistent with this observation. Microarray-
based gene expression studies in CCS confirmed MITF expres-
sion in primary tumor material and cell lines (Schaefer et al.,
2004; Segal et al., 2003). Moreover, these studies demonstrated
the characteristic MITF target gene expression signature in CCS
when compared to other sarcomas, supporting a functional role
for MITF. Precedence for MITF to impose a pattern of melano-
cytic differentiation derives from studies of murine fibroblasts
(Tachibana et al., 1996). However, it is likely that certain con-
text-dependent features contribute importantly to the expres-
sion and differentiation program specified by MITF, such as
the presence of SOX10, which is typically restricted to cells de-
rived from the neural crest and central and peripheral nervous
system (Kuhlbrodt et al., 1998; Pusch et al., 1998; Southard-
Smith et al., 1998). As reported here, SOX10 was required for
MITF expression in CCS. Cotransfection experiments suggest
that CRE-regulated genes are not uniformly activated by chime-
ric EWS-ATF1, implying that additional mechanisms specifyCANCER CELL JUNE 2006
A R T I C L Etarget gene activation (Li and Lee, 1998). MITF may be one of
a restricted group of target genes that exhibit promoter/en-
hancer context specificity, in this case constrained by SOX10.
The apparent absence of M-MITF expression in a single case
of angiomatoid fibrous histiocytoma that expresses EWS-
ATF1 may reflect the absence of requisite SOX10 coexpression
(Hallor et al., 2005) and suggests the existence of alternative tar-
gets of the fusion protein in a different cell lineage.
We demonstrate here that in CCS the EWS-ATF1 fusion pro-
tein acts by targeting MITF to promote tumor cell survival/prolif-
eration. The amplification of MITF in melanoma and its ability to
participate in melanocyte transformation further support the role
of MITF in oncogenesis. It may be interesting in future studies to
examine the effects of EWS-ATF1 expression in melanoma
cells, although it is unclear how its actions may be modulated
by homeostatic mechanisms.
Dysregulation of MITF by EWS-ATF1 in CCS and of TFE3 or
TFEB by translocation in pediatric renal carcinomas suggests
the existence of a discrete family of related human cancers.
The functional relatedness of the MiT oncogenes is supported
by the ability of TFE3 or TFEB to rescue MITF deficiency in
CCS and the reciprocal ability ofMITF to rescue TFE3 deficiency
in pediatric renal cell carcinoma. Melanoma, pediatric renal cell
carcinoma, clear cell sarcoma, and alveolar soft part sarcoma
represent clinically and morphologically distinct malignancies
that would not otherwise be coclassified. However, it is notable
that many of these tumors share not only dysregulated ex-
pression of an MiT transcription factor, but also previously
documented (mis)expression of melanocytic histopathologic
markers, such as HMB45 and melanA/MART1. Since these
markers are now known to be direct transcriptional targets of
MITF in melanocytes and melanoma (Du et al., 2003), it is likely
that they are similarly regulated by TFE3 or TFEB in the other
MiT-associated cancers. The MiT tumors share the characteris-
tic of particular refractoriness to traditional chemotherapeutics
and radiation therapy (Deenik et al., 1999; Kuiper et al., 2003a;
Pappo et al., 1996; Thompson et al., 2005). However, mechanis-
tic insight into these tumors may suggest therapeutic ap-
proaches. For example, a fraction ofmelanomapatients respond
strikingly to various immunotherapeutic modalities, and many of
the antigens implicated as the successful targets of these im-
mune responses are melanocytic differentiation factors (Bakker
et al., 1994; Marincola et al., 1996; Schmollinger et al., 2003).
Several of these are known transcriptional targets of MITF. The
expression of some of these targets in nonmelanomaMiT-asso-
ciated tumors provides a rationale for an immunotherapeutic
approach to treat these diseases. Another theoretical approach
would directly target MiT oncoproteins, recognizing clear chal-
lenges in producing inhibitors of non-ligand-associated tran-
scription factors. Finally, the discovery ofMiT family target genes
important for viability may identify proteins suitable for pharma-
cological suppression. Although likely lacking intrinsic muta-
tions, these proteins may contribute directly to tumor growth
given their hardwired connection to MITF, TFEB, or TFE3.
We have thus demonstrated that MITF is the critical onco-
genic target of EWS-ATF1 in CCS. This observation, taken to-
gether with MiT family amplification and translocations, sup-
ports the hypothesis that multiple mechanisms arise to
dysregulate MiT family members, thereby conferring oncogenic
properties to a transcription factor family otherwise associated
with lineage differentiation. Directed expression of EWS-ATF1CANCER CELL JUNE 2006to generate a mouse model of CCS could provide additional in-
sight into the roles of EWS-ATF1 and the MiT family in solid tu-
mor development. The recognition of shared biologic features in
these seemingly diversemalignancies will hopefully enhance the
discovery of improved therapeutic approaches.
Experimental procedures
Cell culture
DTC-1 (Brown et al., 1995), SU-CCS-1 (Epstein et al., 1984; Zucman et al.,
1993), CCS292, and EWS502 cells were grown in RPMI-1640 supplemented
with 15% fetal bovine serum (FBS) and penicillin and streptomycin. 501mel
cells were grown in Ham’s F-10 with 10% FBS. B16, HEK293, HeLa,
UOK109, and RAW 264.7 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS.
RNA identification and quantitation
Total RNAwaspurifiedwith Trizol (Gibco-BRL).RT-PCRwasperformedusing
Tth DNA polymerase (Roche Molecular Biochemicals) as suggested by the
manufacturer. The 50 primer was specific for theM-MITF isoformRNA (sense,
50-CCTTCTCTTTGCCAGTCCATCTTC-30; antisense, 50-GATCAATCAAGTT
TCCCGAGACAG-30). For quantitative assessment of RNA, 48 hr after cells
were infected RNA was isolated (RNeasy, Qiagen). RNA was subjected to
quantitative PCR using PMEL17 and GAPDH primers as described (Du
et al., 2003).
Chromatin immunoprecipitation
Nuclear extracts were prepared from tissue culture cells as described (Du
et al., 2003). Chromatin immunoprecipitated with polyclonal anti-EWS/FLI1,
anti-CDK2 polyclonal antibody (Santa Cruz), or anti-EWS (BL1083 and
BL1085, Bethyl) were amplified as described (Du et al., 2003, 2004) using
primers directed to the melanocyte-specific MITF promoter (sense, 50-
CTTGAACATTCAGCACAGAGTCTCTT-30; antisense, 50-ACTTTAGCACAGA
ACCCTGCTTATA-30). SYBRGreen (Applied Biosystems) was used to quanti-
tate recovered chromatin.
Transfection, reporter assays, and statistical analyses
Transfections using GeneJammer (Stratagene) or Fugene 6 (Roche) at 3:1 ra-
tio relative to DNA were performed using wild-type or mutant MITF promoter
(2387 to +97) in pGL2basic (Promega) as described (Huber et al., 2003; Price
et al., 1998). Where indicated, cells were treated with forskolin (20 mM;
Sigma), 3-isobutyl-1-methylxanthine (10 mM; Sigma), or H89 (30 mM; Calbio-
chem). SU-CCS-1 cells were transfected by nucleofection (Amaxa) using 3
mg plasmid DNA in solution R using program T20. Two days after transfec-
tion, cells and debris were fixed with 0.5% paraformaldehyde in PBS. GFP
expression was analyzed by fluorescence activated cell sorting (FACS, Facs-
calibur, Becton Dickinson). Trypan-excluding cells were counted. SOX10
and SOX10dom expression constructs were previously described (Huber
et al., 2003). Transfected CCS292 cells were sorted based on GFP cotrans-
fection, using a DakoCytomation High Speed MoFlo Sorter.
Adenovirus generation and infection
To generate dominant-negative CREB adenovirus, the Hind III-XbaI fragment
from FlagCREB M1 was cloned into a CMV-driven shuttle vector containing
IRES-hrGFP and recombined with pAdEasy-1 (He et al., 1998) using BJ5183
cells. The same shuttle vector was used to generate adenoviruses used in
Figure 4 that express murine wild-type MITF or a dominant-negative MITF
lacking amino acids 1–195 (includes transactivation domain) and deleting
the critical basic domain Arg217 (Hemesath et al., 1994; Widlund et al.,
2002). Cells were infected at multiplicities of infection (MOI) between 50
and 200 with CsCl gradient-purified adenovirus as previously described
(Wu et al., 2000).
Tyrosinase pigmentation assay, immunohistochemistry,
and Western blot analysis
Forty-eight or seventy-twohours after adenoviral infection,CCS292cellswere
washedand lysed inPBS/1%TritonX-100with protease inhibitors (Complete,
Boehringer Manheim). Centrifuged supernatants normalized for protein
content (Bio-Rad) were added to 1 mM 3,4-dihydroxy-L-phenylalanine481
A R T I C L E(L-DOPA; Sigma) in PBS, incubated at room temperature, and OD490 was
measured over an 8–12 hr interval using a microplate reader (Model 3550,
Bio-Rad). The slope of the OD versus time plot indicates rate of dopaquinone
pigment formation. For Western blot analyses, anti-SOX10 (Cemines), anti-
MITF (C5), anti-tubulin (Sigma), antiphospho-CREB (9191, Cell Signaling
Technology), CREB (9192, Cell Signaling Technology), or anti-EWS (BL1083,
Bethyl) antibodies were used. Immunohistochemical staining for MITF was
carried out as described (Granter et al., 2001).
Retroviral infection, soft agar, and in vivo growth assays
CCS, Ewing’s sarcoma cells, or HeLa cells were incubated with the appropri-
ate retrovirus prepared as described (Du et al., 2004) in the presence of poly-
brene (8 mg/ml) for 2–16 hr. Two to three days after infection, cells were col-
lected and resuspended in media containing 0.4% noble agar, 13 RPMI,
20% FBS, and puromycin (2 mg/ml) over cell-free bottom agar containing
0.5% noble agar in RPMI (or DMEM for HeLa) with 20% FBS. Cells were cul-
tured several weeks, during which time standard growth media overlaid on
the agar was replaced every 3–5 days. Colonies greater than 1 mm were
counted. UOK109 cells were transfected with relevant plasmids including
a constant amount of pBabe-Puro with Fugene (Roche) at a ratio of 3:2.
Forty-eight hours after transfection, cells were selected with puromycin (3
mg/ml). ForWestern blot analyses, extracts of UOK109 cells weremade after
24 hr of selection. CCS cells were transduced with retrovirus encoding
MMTV-directed expression of luciferase-aminoglycoside phosphotransfer-
ase and selected with Geneticin (0.5mg/ml; Calbiochem). Luc/NeoCCS cells
were transduced with retrovirus expressing EWS-directed shRNA and puro-
mycin N-acetyl transferase as well as LNCX2-MITF retrovirus or LNCX2 ret-
rovirus daily for 2 days, followed by selection in puromycin for 48 hr, after
which all the cells were collected and injected subcutaneously into NCR
nude mice (Taconic). Animals were anesthetized with ketamine and xylazine
and treated with luciferin (Promega) peritoneally followed by imaging (IVIS,
Xenogen). All mouse experimentation was performed under ACUC-approved
DFCI protocol 02-030.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
one supplemental figure and can be found with this article online at http://
www.cancercell.org/cgi/content/full/9/6/473/DC1/.
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